Mouse anti Carcinoma ass. Antigen

175F4 is useful for immunohistochemistry on frozen tissue. Optimal antibody dilution should be determined by titration.

The chance of cure and choice of therapy for squamous carcinomas of the head and neck depend largely on the extent of disease, as assessed clinically by inspection,palpation and radiography. Since treatment failures are in part due to clinically undetected metastasis at the time of treatment, there is a need for more specific methods of tumor detection. Attempts to develop antibodies recognizing tumour-associated antigens have, in the case of carcinomas, resulted in the isolation of a large number of antibodies reactive with high-molecular-weight glycoproteins. Monoclonal antibodies (mAbs) 175F4 (IgG1) and 175F11 (IgG2a), originally raised anti the Human mammary carcinoma cell line (ZR-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins. Immunohistochemically, the mAbs exhibited reactivity with 42 out of 43 squamous cell carcinomas of the head and neck. Normal squamous epithelia are also reactive with the antibodies in the basal and suprabasal cell layer.

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.
This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.

Cancer

Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.

Each vial contains 100 ul 1 mg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.

175F4 is a Mouse monoclonal IgG1 antibody derived by fusion of SP2/0 Mouse myeloma cells with spleen cells from a BALB/c Mouse immunized with EDTA treated Human mammary carcinoma cell line (ZR-75-1).

175F4, which, originally, has been raised anti the Human mammary carcinoma cell line (ZR-75-1), react with a carcinoma-associated antigen in both adenocarcinomas and squamous cell carcinomas of different origins.